Skip to search formSkip to main contentSkip to account menu

GI 147211

Known as: GI-147211, GI147211 
National Institutes of Health

Related topics

Related topics

2 relations
OSI 211

Broader (1)

lurtotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
1997
1997
Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non small cell lung cancer (N)
1996
1996
Identification and characterization of the sulfate precipitate in GI147211C IV formulation.
GI147211, a water soluble analog of camptothecin, is currently being investigated for the treatment of cancer as a topoisomerase… 
1995
1995
High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma.
1995
1995
Determination of GI147211 in human blood by HPLC with fluorescence detection.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)